News

Pharmaceutical Technology on MSN3d
Cingulate secures $3m to advance once-daily anxiety treatment
US biopharmaceutical company Cingulate has announced the receipt of a $3m grant from a private foundation to expedite the ...
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion ...